Europe-wide 360° contract logistics for the pharmaceutical and healthcare industries are becoming even smoother—thanks to the new developments presented at CPHI in Milan.
Unveiled in April 2026, Brenntag's biopharma brand, Byphar, is aimed at companies in the biopharmaceutical industry. Joakim Rehné, President of Brenntag Pharma EMEA, explains the strategy behind the new brand.
CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.
From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.
The European Association of Chemical Distributors (FECC) invites you to embark on a 3-day journey, encompassing unique insights from major value-chain players in combination with lots of facts & figures, ample networking opportunities plus entertainment.
The World Adhesives Conference, taking place only every four years, is the most important event for all stakeholders involved in the adhesive and sealant sector and attracts well over a thousand delegates from all continents. The visitors are adhesive and sealant producers, raw
material suppliers, service providers, scientists and downstream
users.
SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
